Physician profile
Allyson Duda
NPI 1265028914
$1,794.87
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $794.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $338.51 | 2021-2022 | |
| Novo Nordisk INC | $256.42 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $182.34 | 2021-2022 | |
| Amgen INC. | $133.34 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $130.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.32 | 2021 | |
| Glaxosmithkline, LLC. | $78.70 | 2021-2022 | |
| Lilly USA, LLC | $67.30 | 2021-2022 | |
| Abbvie INC. | $63.07 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $57.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $53.52 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.49 | 2022 | |
| Amarin Pharma, INC. | $42.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $33.94 | 2021 | |
| Medtronic, INC. | $28.98 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26.75 | 2021 | |
| Impel Pharmaceuticals INC. | $25.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.33 | 2021 | |
| Upsher-Smith Laboratories LLC | $21.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.41 | 2022 | |
| Pfizer INC. | $16.37 | 2022 | |
| Boston Scientific Corporation | $15.39 | 2021 | |
| Merck Sharp & Dohme LLC | $14.71 | 2021 | |
| Tactile Systems Technology INC | $12.74 | 2021 | |
| Dexcom, INC. | $11.36 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Duda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.